NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq: APLMW) at 9:00 a.m. and 9:05 a.m. Eastern Time, respectively, on October 15, 2025. Trading in the company’s Class A ordinary shares and warrants was halted on September 17, 2025 at 2:37:17 p.m. Eastern Time.
For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.
Nasdaq Media Contact:
Michelle Mendiola
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.19 |
| Daily Change: | 0.02 0.14 |
| Daily Volume: | 4,254 |
| Market Cap: | US$30.360M |
April 03, 2025 March 31, 2025 December 20, 2024 September 04, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
